Skip to main content
main-content

12.05.2017 | Original Article | Ausgabe 8/2017 Open Access

European Journal of Nuclear Medicine and Molecular Imaging 8/2017

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

Zeitschrift:
European Journal of Nuclear Medicine and Molecular Imaging > Ausgabe 8/2017
Autoren:
Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00259-017-3711-7) contains supplementary material, which is available to authorized users.
An erratum to this article is available at http://​dx.​doi.​org/​10.​1007/​s00259-017-3763-8.

Abstract

Purpose

Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.

Methods

We performed a retrospective analysis of 1007 consecutive patients who were scanned with 68Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSADT), PSA velocity (PSAVel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated.

Results

In 79.5% of patients at least one lesion with characteristics suggestive of recurrent PCa was detected. A pathological (positive) PET/CT scan was associated with PSA level and ADT. GSC, amount of injected activity, patient age, PSADT and PSAVel were not associated with a positive PET/CT scan in multivariate analysis.

Conclusion

68Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. Tumour detection is clearly associated with PSA level and ADT. Only a tendency for an association without statistical significance was found between higher GSC and a higher probability of a pathological PET/CT scan. No associations were found between a pathological 68Ga-PSMA-11 PET/CT scan and patient age, amount of injected activity, PSADT or PSAVel.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary File 1 (XLSX 13.5 kb)
259_2017_3711_MOESM1_ESM.xlsx
Supplementary Table 1 (TIFF 17203 kb)
259_2017_3711_MOESM2_ESM.tif
Supplementary File 2 (PDF 509 kb)
259_2017_3711_MOESM3_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2017

European Journal of Nuclear Medicine and Molecular Imaging 8/2017 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.